Bloomberg News

CR Bard Case Over Vaginal Mesh Defects Declared Mistrial (1)

July 10, 2013

CR Bard Inc. (BCR:US) may have to face another jury in a product-liability case over vaginal-mesh devices after a federal judge today declared a mistrial because of a witness’s testimony.

U.S. District Judge Joseph Goodwin in Charleston, West Virginia, stopped the trial in its second day after Lennox Hoyte, a gynecological expert from Tampa, Florida, strayed into testimony about the devices’ marketing. Goodwin had ruled earlier that the plaintiffs couldn’t mention Bard had withdrawn the productS last year.

“I don’t think it’s a bell that can be unrung,” Goodwin said. “It would be very difficult for the jury to disregard.”

Bard, based in Murray Hill, New Jersey, faces at least 3,600 claims over its Avaulta Plus vaginal mesh, which plaintiffs allege can cause internal damage.

Implant makers including Johnson & Johnson (JNJ:US), Endo Health Solutions Inc. (ENDP:US) and Boston Scientific Corp. (BSX:US) face similar claims that their products degrade and shrink over time.

“We’re disappointed the plaintiff’s witness blurted what he did and forced us to ask for a mistrial,” said Lori Cohen, a lawyer for Bard.

The cases are In re C.R. Bard Inc. Pelvic Repair System Products Liability Litigation, 2:10-md-02187, and Cisson v. C.R. Bard Inc., 2:11-cv-00195, U.S. District Court, Southern District of West Virginia (Charleston).

To contact the reporters on this story: Jef Feeley in Charleston, West Virginia, at jfeeley@bloomberg.net; Phil Milford in Wilmington at pmilford@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net


Burger King's Young Buns
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • BCR
    (CR Bard Inc)
    • $146.95 USD
    • 1.12
    • 0.76%
  • JNJ
    (Johnson & Johnson)
    • $102.2 USD
    • 0.01
    • 0.01%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus